Egis Pharmaceuticals PLC

Hungary’s Egis Pharmaceuticals has bolstered its OTC portfolio in its domestic market with the acquisition of skin-care brand Neogranormon from Teva Pharmaceutical Industries for an undisclosed sum. T

Two biosimilar candidates developed by mAbxience will be commercialized in key central and eastern European territories by Egis, under a strategic licensing deal that has just been struck between the

Mundipharma has entered into a distribution partnership with Egis Pharmaceuticals for its Pelmeg (pegfilgrastim) biosimilar. The agreement covers countries in central and eastern Europe (CEE) where

The EU Commission is backing Pfizer Inc. ’s planned purchase of US-based generics firm Hospira Inc. , provided the big pharma sells off some sterile injectable drugs as well as its own biosimila